TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19730280
Drug: Clonazepam 4
Normalized name: Clonazepam 400 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 4 mg
Study: 17089357
Drug: IL-21 +
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-21 + low-dose IL-2
Study: 17089357
Drug: IL-15 +
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-15 + low-dose IL-2
Study: 15361080
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg b.i.d.), ofloxacin (400 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 7 days
Study: 15361080
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg b.i.d.), ofloxacin (400 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 14 days
Study: 9327336
Drug: Intramuscular immunization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular immunization
Study: 8424302
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no calcium channel blocker)
Study: 28638025
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy exercises on the 3rd, 5th, 7th and 9th days of rehabilitation
Study: 26244306
Drug: Tenofovir gel
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir gel (with vaginal concentrations of 10,000 ng/mL or more)
Study: 23578015
Drug: 1.2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg/day atomoxetine for 20 weeks
Study: 18812431
Drug: Cortical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortical stimulation (CS) combined with rehabilitation for 6 weeks, delivered during therapy.
Study: 18812431
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving the same therapy without device implantation or stimulation.
Study: 16904298
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drugs (haloperidol, risperidone, olanzapine, quetiapine)
Study: 3552840
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (SK) treatment
Study: 9578190
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline 10 mg kg(‐1) day(‐1)
Study: 7713093
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral anticoagulation (Group II)
Study: 360120
Drug: Cefazolin (8-hour,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (8-hour, 3-dose regimen)
Study: 31159776
Drug: S&G exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: S&G exercise intervention (combining supervised exercise with gamification and social incentives via WeChat)
Study: 31159776
Drug: S&G exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: S&G exercise intervention
Study: 28296334
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg single dose
Study: 11973484
Drug: 99mTc-DTPA aerosol
Normalized name: DTPA
DrugBank: Pentetic acid (DB14007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 99mTc-DTPA aerosol inhalation scintigraphy
Study: 16865577
Drug: Transdermal estrogen/progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen/progestin
Study: 16865577
Drug: Transdermal estrogen/progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen/progestin and Placebo
Study: 11128344
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 150 mg/daily
Study: 9097868
Drug: High-dose naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naltrexone (100 mg bid) followed by 200 mg bid during open-label period
Study: 3539851
Drug: Prophylactic systemic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic systemic antibiotics (PSA)
Study: 26598744
Drug: Lapatinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib + Trastuzumab (L+T)
Study: 26598744
Drug: Trastuzumab followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab followed by Lapatinib (T->L)
Study: 23887684
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine premedication followed by intraoperative saline infusion (group A)
Study: 23887684
Drug: Placebo premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo premedication followed by dexmedetomidine infusion (group B)
Study: 11017811
Drug: Prednisolone, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, 60 mg/day for 2 weeks
Study: 9251115
Drug: Hepatic intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hepatic intra-arterial (HIA) chemotherapy
Study: 1609034
Drug: Haloperidol treatment
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol treatment with 50% dose decrease
Study: 3303753
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of MTX and 5-FU (therapy arm A)
Study: 3303753
Drug: Systematic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic treatment with CMFV combination (therapy arm B)
Study: 25156082
Drug: Luliconazole cream
Normalized name: Luliconazole Cream
DrugBank: Luliconazole (DB08933)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Luliconazole cream 1%
Study: 20332720
Drug: Alcohol injection
Normalized name: Dehydrated Alcohol Injection Solution
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol injection to the motor branches of tibial nerve
Study: 20332720
Drug: Phenol injection
Normalized name: Phenol Injection
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenol injection to the motor branches of tibial nerve
Study: 16607468
Drug: Pramipexole (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (1.5 to 4.5 mg/day)
Study: 14615578
Drug: Antidepressant (nefazodone)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant (nefazodone)
Study: 14615578
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antidepressant and psychotherapy
Study: 455950
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of psychotherapy and pharmacotherapy
Study: 10524470
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone given every 12 hours
Study: 10524470
Drug: Immediate-release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxycodone given four times daily
Study: 9586597
Drug: Alpha-blockers
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blockers
Study: 1975246
Drug: Beta-blockers with
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers with concurrent alpha-blocker
Study: 7009255
Drug: Clomipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25 mg daily)
Study: 28719669
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (SUPP; n = 25; 30 g whey protein, 2.5 g creatine, 500 IU vitamin D, 400 mg calcium, 1500 mg n‐3 PUFA)
Study: 28719669
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (SUPP + EX)
Study: 28719669
Drug: Control (CON;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (CON; n = 24; 22 g of maltodextrin)
Study: 11760164
Drug: Clinafloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinafloxacin (200 mg/d)
Study: 11760164
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g/d; with or without erythromycin)
Study: 9408806
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day) plus placebo for 4 weeks
Study: 9408806
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day) plus pindolol (7.5 mg/day) for 1 week and placebo for 3 weeks
Study: 9408806
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day) plus pindolol (7.5 mg/day) for 4 weeks
Study: 9408806
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day) plus metoprolol (50 mg/day)
Study: 23772856
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM), 750 mg, two doses, 1 week apart (Group A)
Study: 23772856
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM), 750 mg, two doses, 1 week apart (Group C)
Study: 23772856
Drug: Oral iron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron, 325 mg, 3 times a day for 14 days (Group B)
Study: 20705778
Drug: Ultrasound guidance
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guidance (UG) with 1.5% mepivacaine, starting dose 13 mL for median nerve
Study: 20705778
Drug: Neurostimulation (NS)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurostimulation (NS) with 1.5% mepivacaine, starting dose 11 mL for ulnar nerve
Study: 19117154
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% + sufentanil 0.75 microg mL‐1 (Group-I)
Study: 8903809
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketorolac
Study: 23943850
Drug: Levamisole hydrochloride
Normalized name: Levamisole Hydrochloride
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole hydrochloride (150 mg)
Study: 23943850
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant to antimalarial treatment (Control)
Study: 17701094
Drug: Low fluoride
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fluoride dose (≤20 mg fluoride equivalents)
Study: 17701094
Drug: Fluoride treatment
Normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride treatment with daily dose >20 mg fluoride equivalents
Study: 12803658
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (clipping)
Study: 7912947
Drug: Balanced anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced anaesthesia with fentanyl (4 micrograms kg‐1 bolus followed by 1 microgram kg‐1 h‐1 infusion)
Study: 2598976
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg i.v.
Study: 20147814
Drug: Serum CTX
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CTX test performed preoperatively in 54 patients taking oral bisphosphonates (BPs)
Study: 20147814
Drug: No CTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No CTX test performed in 109 patients taking oral BPs (control group)
Study: 15669886
Drug: Paroxetine CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine CR (25-75 mg/day)
Study: 9257379
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream 0.025%
Study: 12889719
Drug: Tretinoin microsphere
Normalized name: tretinoin microsphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin microsphere gel 0.1%
Study: 12963899
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adapalene gel 0.1% with various antimicrobial agents
Study: 9234040
Drug: 24-hr patch
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hr patch
Study: 9234040
Drug: 16-hr patch
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-hr patch
Study: 9234040
Drug: 24-hr patch
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hr patch plus gum
Study: 9234040
Drug: Double 24-hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double 24-hr patch
Study: 7961259
Drug: Inspiratory flow-resistive
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow-resistive loading (L2: 125 cmH2O.l‐1.s)
Study: 7961259
Drug: Inspiratory flow-resistive
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow-resistive loading (L3: 250 cmH2O.l‐1.s)
Study: 3475725
Drug: Intra-amniotic 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic 1.5 mg 15(S) 15 methyl PGF2 alpha (PGF2 alpha)
Study: 3475725
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg and 50 mg orally three and one hour before PGF2 alpha
Study: 2076744
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal suspension (5 g as 200 ml)
Study: 2076744
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal tablets (40 of 125 mg)
Study: 2076744
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal capsules (25 of 200 mg)
Study: 2076744
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (suspension medium without AC)
Study: 1215547
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg X 4 over 24 hours)
Study: 1215547
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg X 6 over 36 hours)
Study: 26978624
Drug: Advanced techniques
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced techniques including minimally invasive surgical sanitation of infected fracture zone followed by differentiated tactics of consistent and gradual minimally invasive functionally stable osteosynthesis with modern APS and implants on a background of conservative therapy consisting of Cycloferon.
Study: 23888318
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2 g/day)
Study: 23888318
Drug: High-oleic sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-oleic sunflower oil (8 g/day)
Study: 23888318
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2 g/day) and High-oleic sunflower oil (8 g/day)
Study: 15536111
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg/d for 6 months
Study: 11238151
Drug: 0.97 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.97 mg/kg amphotericin B by continuous infusion over 24 hours
Study: 11238151
Drug: 0.95 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.95 mg/kg amphotericin B by rapid infusion over four hours
Study: 30543461
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg thrice daily for 14 days)
Study: 27484978
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise plus pharmacotherapy
Study: 27484978
Drug: Only pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only pharmacotherapy
Study: 26033708
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with paclitaxel plus gemcitabine (PG)
Study: 24717377
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with sertraline
Study: 22007522
Drug: Lisinopril/hydrochlorothiazide combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril/hydrochlorothiazide combined tablets (high, medium, low doses)
Study: 22007522
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of lisinopril/hydrochlorothiazide combined tablets
Study: 22007522
Drug: Lisinopril (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (test medication)
Study: 22007522
Drug: Hydrochlorothiazide (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (test medication)
Study: 8620790
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine 20 mg
Study: 6381432
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusions of BUdR and IUdR
Study: 29695500
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored rituximab regimen (500 mg infusion at randomisation, reinfusion based on CD19+B lymphocytes or ANCA levels)
Study: 29695500
Drug: Fixed-schedule rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed-schedule rituximab regimen (500 mg infusion on days 0 and 14, then at 6, 12, and 18 months)
Study: 24118023
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg day(-1) for 4 weeks
Study: 24118023
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg day(-1) for 4 weeks
Study: 24118023
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg day(-1) for 4 weeks
Study: 12578924
Drug: Healthy control
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy control group (no treatment)
Study: 18521686
Drug: Cytoreduction followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC) and systemic chemotherapy
Study: 18521686
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy alone (Control)
Study: 10048613
Drug: rHuEPO (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (300 IU/kg three times a week s.c.) and oral iron (ferrofumarate, 6 mg of iron/kg per day)
Study: 10048613
Drug: rHuEPO (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (300 IU/kg three times a week s.c.) and intramuscular iron (ferroxypolymaltose, once 12 mg of iron/kg weekly)
Study: 10048613
Drug: Intramuscular iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular iron (ferroxypolymaltose, once 12 mg of iron/kg weekly) without rHuEPO
Study: 375461
Drug: Atropine methonitrate
Normalized name: Atropine methonitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine methonitrate 2 mg
Study: 375461
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salbutamol and atropine methonitrate
Study: 27354046
Drug: Intravenous procainamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous procainamide (10 mg/kg/20 min)
Study: 27354046
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (5 mg/kg/20 min)
Study: 27354046
Drug: Intravenous procainamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous procainamide (10 mg/kg/20 min) in patients with structural heart disease
Study: 27354046
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (5 mg/kg/20 min) in patients with structural heart disease
Study: 2578352
Drug: Running under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Running under hot conditions (rectal temperature increase averaging 2.3 degrees C)
Study: 2578352
Drug: Running with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Running with additional cooling (rectal temperature rise reduced to an average of 1.0 degree C)
Study: 37045
Drug: Dexchlorpheniramine 4
Normalized name: dexchlorpheniramine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexchlorpheniramine 4 mg
Study: 18612151
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus chemotherapy (paclitaxel plus carboplatin)
Study: 15695472
Drug: Polarity Therapy
Normalized name: Adlarity
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polarity Therapy (PT) treatments (1 or 2 treatments)
Study: 15695472
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PT treatments)
Study: 12406667
Drug: beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone dipropionate bid (800 mcg) via jet nebulizer
Study: 12406667
Drug: beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone dipropionate bid (800 mcg) via ultrasonic nebulizer